Background-Previous studies suggested that statin pretreatment reduces cardiac events in patients undergoing percutaneous coronary intervention. However, most data were observational, and single randomized trials included limited numbers of patients. Methods and Results-We performed a collaborative meta-analysis using individual patient data from 13 randomized studies in which 3341 patients received either high-dose statin (nϭ1692) or no statin/low-dose statin (nϭ1649) before percutaneous coronary intervention, with all patients receiving statin therapy after intervention. Occurrence of periprocedural myocardial infarction, defined as postintervention creatine kinase-MB increase Ն3 times the upper limit of normal, and 30-day major adverse cardiac events (death, myocardial infarction, target-vessel revascularization) was evaluated. Incidence of periprocedural myocardial infarction was 7.0% in the high-dose statin versus 11.9% in the control group, which corresponds to a 44% risk reduction in the active-treatment arm (odds ratio by fixed-effects model 0.56, 95% confidence interval, 0.44 to 0.71, PϽ0.00001). The rate of major adverse cardiac events at 30 days was significantly lower in the high-dose statin group (7.4% versus 12.6%, a 44% risk reduction; PϽ0.00001), and 1-month major adverse cardiac events, excluding periprocedural events, were also reduced (0.6% versus 1.4%; Pϭ0.05). The benefit of high-dose statins was realized irrespective of clinical presentation (P for interactionϭ0.43) and was maintained across various subgroups but appeared greater in the subgroup with elevated baseline C-reactive protein levels (nϭ734; 68% risk reduction for periprocedural myocardial infarction versus 31% in those 1861 patients with normal CRP; P for quantitative interactionϭ0.025). Conclusions-High-dose statin pretreatment leads to a significant reduction in periprocedural myocardial infarction and 30-day adverse events in patients undergoing percutaneous coronary intervention. This strategy should be considered in all patients with planned percutaneous coronary intervention. (Circulation. 2011;123:1622-1632.)
improvement of antithrombotic therapy, have been evaluated to decrease the incidence of cardiac ischemic events during PCI (use of glycoprotein IIb/IIIa antagonists, ␤-blockers, optimization of clopidogrel loading, and new antiplatelet agents). 6 -10 
Clinical Perspective on p 1632
In the last few years, experimental studies demonstrated that statins have cardioprotective effects in the animal model of ischemia/reperfusion, 11, 12 and clinical data indicated that pretreatment with statins may significantly reduce periprocedural complications and major adverse cardiac events (MACE) in patients undergoing PCI [13] [14] [15] ; however, those data mainly derive from observational studies, whereas single randomized trials on this topic included a limited number of patients and were not powered to evaluate post-PCI events. 16 -28 It may be difficult to reach definitive conclusions on the basis of the results of individual studies; thus, we performed a collaborative patient-level meta-analysis of randomized, controlled trials that evaluated the clinical benefit of statin pretreatment in the setting of PCI to quantify the effect of such therapy on the reduction of periprocedural myocardial infarction and MACE at 30 days.
Methods

Data Sources and Selection Criteria
The MEDLINE and PubMed databases (from 1996 to 2010) were searched, and cited references were reviewed to identify prospective randomized trials that compared the clinical outcome of high-dose versus no statin or low-dose statin pretreatment in patients undergoing PCI. Search keywords were "statins," "statin," "atorvastatin," "rosuvastatin," "cerivastatin," "simvastatin," "pravastatin," "lovastatin," and "hydroxymethylglutaryl-CoA," combined with the words "angioplasty," "stent," "coronary," and "randomized." No restriction on subheadings was applied. Presentations at major cardiology congresses (meetings of the European Society of Cardiology, American College of Cardiology, and American Heart Association) were checked through meetings proceedings, official Web sites, and direct attendance at the meetings. All references of relevant trials were also reviewed.
Data Collection
We included 13 clinical trials; full descriptions of the study designs, sample characteristics, treatment protocols, and outcome findings have been reported elsewhere. 16 -28 No identified studies were excluded. Principal investigators of each of the 13 trials were invited to send the requested patient-level data regarding main clinical and procedural features in the study population, as well as individual outcome data, including levels of creatine kinase-MB (CK-MB) and troponin before and after intervention; periprocedural highsensitivity C-reactive protein (CRP) levels; and occurrence of death, stent thrombosis, unplanned target-vessel revascularization, myocardial infarction up to 30 days, or relevant drug-related side effects. Of the 13 studies, 12 agreed to participate in the patient-level analysis and 1 declined. 22 An electronic form that contained those data fields to be completed for individual patients was sent to the principal investigators who agreed to participate. All data were verified thoroughly for consistency (logical checking and checking against the original publications). Any disagreements were resolved, and final database entries were verified by the responsible trial investigator.
Quality of the Studies
Studies were evaluated for the adequacy of allocation concealment and performance of the analysis according to the intention-to-treat principle. Criteria previously described by Altman and Schulz 29 were used to determine adequate concealment of the treatment allocation. We did not perform weighting of the studies by quality scores because this practice has been discouraged previously in controlled clinical trials. 30 
End-Point Definitions
Individual data were pooled for comparison of the incidence of periprocedural myocardial infarction and MACE at 30 days in the 2 arms (high-dose statin pretreatment versus control). The control group included patients who received either no statin or low-dose statin before PCI.
For the purpose of this meta-analysis, to allow optimal comparability, a standard definition of periprocedural infarction was applied for all studies according to the universal definition, 31 even if the study used a different definition of periprocedural myocardial infarction: In patients with stable angina or non-ST-segment elevation acute coronary syndrome (ACS), periprocedural infarction was defined as a postintervention CK-MB increase Ն3 times the upper limit of normal (ULN), whereas in patients with ST-segment elevation myocardial infarction, it was defined as a Ն20% increase from the baseline value in CK-MB or troponin levels in the second sample drawn after 3 to 6 hours. A secondary analysis of periprocedural myocardial injury was defined as any postintervention elevation of troponin levels Ͼ1ϫULN. Other exploratory definitions of periprocedural myocardial ischemic events included post-PCI CK-MB raise Ͼ1ϫULN and troponin elevation Ն3ϫULN. We also report data according to the "per trial" definition of periprocedural myocardial infarction.
The composite end point of the analysis was incidence of MACE, defined as death, myocardial infarction, or target-vessel revascularization, by 30 days. Other MACE end points were evaluated for consistency, including death, myocardial infarction, target-vessel revascularization, or stent thrombosis by 30 days, as well as both MACE end points using only spontaneous myocardial infarction rather than both spontaneous infarction and periprocedural infarction. The components of the MACE end points were also evaluated individually.
Outcome data were available through 30 days for all patients of the included studies, except those by Bozbas et al, 24 Jia et al, 26 and Cay et al, 28 which collected data only on in-hospital events. In addition, the study by Veselka et al, 22 who did not participate in the patient-level meta-analysis, did not evaluate the 30-day clinical outcome. For those 4 studies, which comprised 820 patients, inhospital events were used for the MACE end point. Periprocedural high-sensitivity CRP level variation (postintervention CRP minus baseline CRP) was evaluated in the 2 groups when those data were available, as was the incidence of periprocedural infarction according to baseline CRP levels.
Statistical Analysis
A patient-level pooled analysis was performed to evaluate the effect of pretreatment with high-dose statin on outcome measures. The analysis was performed according to the intention-to-treat strategy. Percentages are presented for discrete variables and meanϮSD or median (with 25th and 75th percentiles) for continuous variables. Continuous variables were compared with the Wilcoxon rank sum test. Differences between randomized groups for categorical variables were compared with a 2 test or Fisher exact test, as appropriate. Treatment effects were estimated from logistic regression models and reported as odds ratio (OR) with 95% confidence intervals (CIs). Subgroup analysis was performed in subjects by index event of stable angina versus ACS and by use of glycoprotein IIb/IIIa inhibitors, as well as according to other features (age, sex, diabetes mellitus versus no diabetes, single-vessel versus multivessel intervention, and presence or absence of elevated CRP).
To evaluate the robustness of the findings and the impact of the 1 study that declined to participate in the patient-level analysis, we conducted a trial-level meta-analysis using the event rates in the high-dose statin and control arms for each trial. The meta-analysis was performed of the relative odds based on fixed-effects models. A test of heterogeneity, which evaluates variability in the treatment effects, was performed by the Mantel-Haenszel method. The possibility of publication bias was assessed by funnel plot analysis. 32 
Results
Main Features of Included Studies
Data from the aforementioned 13 prospective randomized trials 16 -28 that evaluated the effects of high-dose statin pretreatment on clinical outcome in patients undergoing PCI were analyzed (Table 1) ; 3341 patients were included in the analysis, 1692 of whom were randomized to highdose statin and 1649 to low-dose or no statin therapy (control group).
The clinical presentation of the patients included in the studies and the drug assignment before PCI are indicated in 20 and the study by Hara et al 27 ) included statin-naive patients. In all studies, patients received statin therapy after the intervention irrespective of the initial randomization assignment ( Table 1) .
The pre-PCI bolus of unfractionated heparin was similar: 5000 IU in the studies by Yun et al 19 and Jia et al, 26 50 to 80 IU/kg in the study by Veselka et al, 22 70 to 100 IU/kg in the studies by Bozbas et al 24 and Cay et al, 28 100 IU/kg in the study by Hara et al, 27 and 70 IU/kg in the 3 ARMYDA trials, 16, 18, 20 the 2 studies by Briguori et al, 17, 21 and the study by Kinoshita et al. 25 In STATIN STEMI (Efficacy of HighDose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction), 23 weight-adjusted unfractionated heparin was given to achieve a target activated clotting time of Ͼ300 seconds in the absence of glycoprotein IIb/IIIa inhibitors and 200 to 300 seconds with glycoprotein IIb/IIIa inhibitors. Bivalirudin was used instead of unfractionated heparin in 10% of patients in ARMYDA-RECAPTURE 20 and enoxaparin in 37% of those in the study by Yun et al. 19 Patients in all studies were pretreated with aspirin; the ARMYDA trials and STATIN STEMI 16, 18, 20, 23 used 600 mg of clopidogrel as a loading dose, 5 studies 19,21,22,24,28 used a 300-mg loading dose, 3 studies 17, 25, 26 used either ticlopidine or clopidogrel (75 mg/d) starting Ն3 days before PCI, and ticlopidine or cilostazol was given in the study by Hara et al. 27 Glycoprotein IIb/IIIa inhibitors were not used in 4 studies, 22, 24, 25, 27 whereas such agents were administered, at the discretion of the operator, in the following proportions of patients in the other studies: 52% in the studies by Briguori et al, 17 24% in ARMYDA-ACS, 18 20% in ARMYDA 16 and in the study by Jia et al, 26 14% in NAPLES (Novel Approaches for Preventing or Limiting Events) II 21 and in the study by Cay et al, 28 12% in ARMYDA-RECAPTURE, 20 7% in the study by Yun et al, 19 and 22% in STATIN STEMI. 23 There were no differences in periprocedural antithrombotic therapies between high-dose statin pretreatment and control groups in any of the studies.
Main demographic, clinical, and procedural features in the overall population are reported in Table 2 . The prevalence of patients with age Ն65 years was approximately 50%; 39% of patients had ACS, and 28% had diabetes mellitus.
Periprocedural Outcome
Patient-level analysis demonstrated that overall, periprocedural myocardial infarction occurred in 6.8% of patients in the high-dose statin pretreatment group versus 11.9% of those in the control group, which corresponds to a 46% relative reduction in the active-treatment arm (OR, 0.54, 95% CI, 0.42 to 0.70; PϽ0.00001). When data from the study by Veselka et al 22 were added in a trial-level analysis, the findings for periprocedural myocardial infarction were consistent: 7.0% versus 11.9%, a 44% relative risk reduction (OR, 0.56, 95% CI, 0.44 to 0.71; PϽ0.00001; Table 3 ; Figure 1 ). There was no evidence of significant heterogeneity among the 13 trials (Pϭ0.62, I
2 ϭ0%), and funnel plot analysis did not suggest the presence of publication bias ( Figure 1 ). High-dose statin pretreatment was also associated with a significantly lower incidence of periprocedural myocardial infarction per trial definition (6.8% versus 15.1% in the control arm; OR, 0.40, 95% CI, 0.32 to 0.51; PϽ0.00001).
Moreover, after high-dose statin pretreatment, there was a decreased incidence of periprocedural myocardial injury (defined as any post-PCI elevation of troponin levels above the ULN): 34.9% versus 47.7% in the control group (OR, 0.59, 95% CI, 0.51 to 0.68; PϽ0.00001). When data from the study by Veselka et al 22 were added in a trial-level analysis, the findings for periprocedural myocardial injury were consistent: 35.8% versus 47.9% (OR, 0.57, 95% CI, 0.49 to 0.67; PϽ0.00001; Table 3 ). Results according to other exploratory definitions of periprocedural myocardial ischemic events are indicated in Table 3 . Maximum CK-MB/ULN ratio and maximum troponin/ ULN ratio after PCI were also significantly lower in the high-dose statin group (CK-MB: median 0.7 ng/mL, interquartile range 0.4 to 1.1 ng/mL versus 0.8 ng/mL, interquartile range 0.5 to 1.6 ng/mL [Pϭ0.00001]; troponin: median 0.4 ng/mL, interquartile range 0.1 to 1.8 ng/mL versus 0.8 ng/mL, interquartile range 0.2 to 3.8 ng/mL [Pϭ0.00001]).
Adverse Events at 30 Days
The proportion of patients with MACE (including periprocedural myocardial infarction) at 30 days was lower in the high-dose statin pretreatment group (7.4% versus 12.6%; OR, 0.56, 95% CI, 0.44 to 0.71; PϽ0.00001; Table 3 ; Figure 2 ); this outcome was mainly driven by periprocedural events in either arm (Figure 3 ). There was no evidence of significant heterogeneity among the trials with regard to outcome data through 1 month (Pϭ0.54, I 2 ϭ0%; Figure 2 ). However, when only spontaneous myocardial infarctions (ie, not periprocedural infarctions) were counted, rates of MACE were 0.6% in the high-dose statin group versus 1.4% in the control arm, with an OR of 0.44 (95% CI, 0.19 to 1.01; Pϭ0.05), consistent with the overall result shown for MACE that included periprocedural myocardial infarction (Table 3) . Complete outcome data at 30 days are reported in Table 3 ; in particular, 30-day mortality was 0.24% in the high-dose statin group versus 0.56% in the control group (OR, 0.42, 95% CI, 0.11 to 1.64; Pϭ0. 20) , and target-vessel revascularization occurred in 0.32% versus 0.80% (OR, 0.39, 95% CI, 0.12 to 1.26; Pϭ0. 10) . No significant side effects (aspartate transaminase/alanine transaminase or CK elevation Ͼ3ϫ ULN) were associated with statin pretreatment in any study.
CRP Data
High-sensitivity CRP levels were measured in 9 studies. 16 -21,24,26,27 Periprocedural CRP-level variation (postintervention CRP minus baseline CRP) was lower in patients who received In the subgroup of 1861 patients with normal baseline CRP levels (by trial definition), incidence of periprocedural myocardial infarction was 7.8% in the high-dose statin group versus 10.9% in the control group, whereas in those 734 patients with elevated CRP levels, it was 4.3% versus 12.3%, respectively ( Figure 4) ; the OR for periprocedural myocardial infarction in favor of high-dose statin pretreatment was 0.69 (95% CI, 0.50 to 0.95; Pϭ0.021) in patients with normal CRP levels and 0.32 (95% CI, 0.18 to 0.58; PϽ0.001) in those with elevated CRP levels (P for quantitative interactionϭ0.025, ie, both analyses were in the same direction in favor of high-dose statins, but the effect was greater in the subgroup with elevated CRP).
Outcome According to Various Clinical Features
We pooled data to evaluate the grade of benefit provided by high-dose statin pretreatment according to clinical presentation on admission ( Figure 5 ). In the subgroup with stable angina (nϭ2293), high-dose statin pretreatment was associated with a lower incidence of periprocedural myocardial infarction (7.5% in the high-dose statin group versus 13.2% in the control group, which corresponds to a 48% relative risk reduction [OR, 0.52, 95% CI, 0.41 to 0.66; Pϭ0.00001]). In patients presenting with ACS (nϭ1032), periprocedural myocardial infarction occurred in 5.9% of patients in the highdose statin group and 9.0% of those in the control group (OR, 0.64; 95% CI, 0.40 to 1.02; Pϭ0.06). The interaction test for clinical presentation was not significant (Pϭ0.43).
The ORs for periprocedural myocardial infarction in favor of high-dose statin pretreatment were 0.71 (95% CI, 0.45 to 1.12; Pϭ0.16) in patients receiving glycoprotein IIb/IIIa inhibitors (nϭ603) and 0.49 (95% CI, 0.36 to 0.66; Pϭ0.00001) in those not receiving these agents (nϭ2519; P for interactionϭ0.18). Patient-level analysis demonstrated that periprocedural myocardial protection by high-dose statin pretreatment was maintained across other subgroups of patients ( Figure 5 ).
Discussion
This collaborative patient-level meta-analysis shows that pretreatment with high-dose statins significantly reduces the risk of adverse cardiac events and periprocedural myocardial infarction in patients undergoing PCI. The finding was robust across all the trials, and was present both in patients who were undergoing PCI after ACS and in those with stable angina. In addition, the benefit was observed in patients receiving dual-antiplatelet therapy (aspirin and a thienopyridine) and in those receiving triple-antiplatelet therapy (also receiving glycoprotein IIb/IIIa inhibitors). High-dose statin therapy reduced high-sensitivity CRP levels over the 24-hour period immediately after PCI, which suggests that the antiinflammatory effect of statins may be a mechanism by which such therapy decreases periprocedural events. Previous studies have shown that statin therapy, when initiated early after the procedure, improves clinical outcome in patients undergoing PCI. 33 Moreover, data have suggested that patients taking statins at the time of PCI have a lower incidence of periprocedural cardiac ischemic events than those who are statin naive [13] [14] [15] ; however, those studies were observational and nonrandomized, and included patients with various risk profiles treated with different statins at variable doses and with variable duration of therapy. This is critical, and thus, the meaning of such observational data is questionable and must be considered hypothesis generating. In the last few years, prospective randomized studies have evaluated the issue of whether a statin pretreatment, with fixed doses of a specific agent for a short, definite period, may provide periprocedural cardioprotection in the setting of PCI; the majority of such studies demonstrated a benefit, 16 -21,23,25-28 but they did not include large numbers of patients, and 2 studies were not confirmatory. 22, 24 Therefore, only pooled analyses that include a large patient population may help to achieve definitive results; a meta-analysis 34 was initially performed on this issue, but it had relevant limitations because it included only 2 prospective trials, which were added into the same analysis as retrospective studies. Three other meta-analyses [35] [36] [37] have been published recently that demonstrated the effectiveness of a statin pretreatment in the setting of PCI, but those investigations did not include the newest randomized studies, were conducted at a study level, did not perform time-to-event and subgroup analyses, did not evaluate occurrence of combined and individual MACE, and considered the incidence of periprocedural myocardial infarc- tion only according to the per trial definition. The present meta-analysis, which included 3341 patients and was performed at a patient level by a fixed-effects model, owing to the lack of heterogeneity, indicates that a short-term, highdose statin pretreatment significantly reduces the incidence of periprocedural myocardial infarction in patients undergoing PCI when a universal, contemporary definition of such a complication 31 is used; in particular, use of high-dose statins was associated with a 44% risk reduction for periprocedural infarction, and 20 patients would need to be treated to avoid 1 event. High-dose statin pretreatment decreased the rate of periprocedural myocardial infarction even when a per trial definition was applied (60% risk reduction), and it decreased the rate of periprocedural myocardial injury defined by any troponin elevation (43% risk reduction). Occurrence of periprocedural myocardial infarction by cardiac marker elevation, even if clinically silent, may affect cardiovascular outcome and overall survival in patients treated with PCI 5 ; of note, the relative increase in mortality at 6 months associated with each elevation of CK-MB values has been demonstrated to be similar for both spontaneous and PCI-related myocardial necrosis. 38 Furthermore, previous studies demonstrated a correlation between the degree of postprocedural CK-MB increase and mortality risk during follow-up [2] [3] [4] ; in particular, a meta-analysis that pooled data from 23 230 patients 5 showed that the excess mortality at 1 year was 1.7%, 2.8%, and 7.4% for patients with postintervention CK-MB elevation of 1 to 3 times ULN, 3 to 5 times ULN, and Ͼ5 times ULN, respectively. Thus, therapeutic strategies able to reduce the incidence of periprocedural myocardial injury may favorably influence clinical outcome after PCI. Although there is irrefutable evidence that periprocedural myocardial injury results in higher mortality rates during long-term follow-up, a meta-analysis assessing the long-term benefit of high-dose statin pretreatment before PCI might add even more substantial evidence for this particular treatment modality.
In the present meta-analysis, patients pretreated with highdose statins also had a 44% reduction in risk of 30-day MACE after intervention (number needed to treatϭ19). Although the incidence of MACE may have been statistically accounted for in part by periprocedural myocardial infarction, other individual outcome measures, including spontaneous myocardial infarction, 30-day mortality, and target-vessel revascularization, were all considerably lower in the highdose statin arm, although these were not significant owing to the small number of end points attained in these subgroup analyses; future studies may well provide results for a larger number of patients, thereby allowing a much more informative review of these potential benefits.
The incidence of MACE that did not include periprocedural myocardial infarction was lower in the high-dose statin group (0.8% absolute reduction, 56% relative reduction), which was of borderline significance because of the low event rate but was similar to the overall finding for MACE that included periprocedural myocardial infarction; importantly, this occurred despite the fact that all patients continued statin treatment after intervention irrespective of initial randomization assignment and that in the control arm, statin therapy was initiated early after PCI. No evidence of publication bias was found in the results of the present meta-anal- ysis, and no heterogeneity among the trials was found, despite differences in the study designs. Moreover, when individual data were pooled, subgroup analysis revealed that the clinical benefit of high-dose statin pretreatment was significant irrespective of clinical presentation (48% reduction in risk of periprocedural infarction in stable angina and 36% in ACS). Because the absolute number of patients with ACS was relatively low, a need remains for a large randomized, controlled trial to focus on the relevant MACE and periprocedural myocardial infarction reduction observed in the present meta-analysis in this subset. Patients with severe renal failure or with liver or muscle disease were excluded from all trials by protocol, and this precluded assessment of a benefit of high-dose statin in those subgroups of patients.
The possible mechanisms underlying the early protective action of statins are unclear, but are not likely due to cholesterol-lowering effects, because all trials included in the analysis used a short-term pretreatment with high-dose statin (median 0.5 days), which did not produce significant effects on cholesterol levels. Various studies demonstrated early lipid-independent (ie, pleiotropic) effects of statins, including antithrombotic action, 39 improvement of coronary flow velocity reserve by vasodilation of coronary microvessels, 40 and rapid (Ͻ12 hours after a single dose of atorvastatin) improvement of endothelial function 41 ; in particular, a planned subanalysis of the ARMYDA trial 42 showed that myocardial protection conferred by atorvastatin is paralleled by attenuation of procedural endothelial activation, with significant reduction of adhesion molecules to peak levels after intervention. Furthermore, in STATIN STEMI, 23 pretreatment with high-dose atorvastatin before primary PCI improved microvascular coronary perfusion and ST-segment resolution rates compared with low-dose atorvastatin. A higher inflammatory status in patients undergoing PCI is associated with enhanced risk of periprocedural complications and cardiac events during follow-up. 43, 44 Statins have anti-inflammatory effects both in vitro and in vivo. 45, 46 In the present meta-analysis, high-dose statin pretreatment was associated with a lower post-PCI increase in CRP levels and provided periprocedural cardioprotection mainly in the subgroup with elevated baseline CRP values; because 4 studies did not perform measurement of CRP levels, the study groups without CRP determination might have differed in some way. The present meta-analysis provides additional evidence to support the subclinical inflammatory hypothesis of atherosclerosis and a likely mechanism by which highdose statins are beneficial as pretreatment for PCI. However, patients with normal levels of high-sensitivity CRP have a greatly reduced OR when treated with high-dose statins compared with control subjects; this suggests that other mechanisms may be at play that may ultimately influence outcome during or after PCI. All of the aforementioned pleiotropic effects of statins might contribute to decrease myocardial necrosis due to procedural microembolization in the setting of PCI. In particular, patients with ACS and high inflammatory status, in whom there is a complex interaction between endothelial dysfunction/activation, inflammation, and thrombosis, may derive a relevant benefit from early high-dose statin therapy before an invasive strategy.
Experimental data in mice have demonstrated that acute administration of a statin can reduce infarct size after ligation of the left anterior descending artery and subsequent reperfusion 11, 12, 47 ; this animal model has enabled in-depth experiments on the molecular mechanisms of this cardioprotection. In particular, the beneficial effect of atorvastatin may share the same molecular mechanisms as ischemic preconditioning, ie, activation of nitric oxide synthase and promotion of cyclooxygenase-2 and prostaglandin I2. 47, 48 Atorvastatin induces rapid (within 5 minutes) activation of the phosphatidylinositol 3-kinase and serine/threonine kinase (Akt) signaling cascades, which in turn causes phosphorylation and activation of nitric oxide synthase. 12 The beneficial effect of atorvastatin on infarct size is absent in nitric oxide synthase knockout mice and may be reversed by administration of specific inhibitors of phosphatidylinositol 3-kinase or nitric oxide synthase. 12, 47 Interestingly, the acute protective effect of atorvastatin on myocardial injury in the animal model may wane with a longer treatment, but this effect can be recaptured by a "reloading" given immediately before ischemia/ reperfusion. 48 In the ARMYDA-RECAPTURE trial, 20 shortterm pretreatment with a high-dose atorvastatin load before PCI was associated with improved periprocedural outcome even in patients undergoing chronic statin therapy, who represent a relevant proportion of those patients receiving percutaneous revascularization.
Although results of retrospective studies (which included patients receiving a multitude of statins) may suggest the presence of a class effect, the large majority of prospective randomized trials demonstrating periprocedural cardioprotection by statins in patients undergoing PCI used a short-term pretreatment with high doses of a potent statin (atorvastatin or rosuvastatin). In particular, studies using atorvastatin 80 mg and rosuvastatin 40 mg before PCI represented 54% and 19%, respectively, of the overall weight in the present meta-analysis. Thus, when a strategy of short-term pretreatment with statins before PCI is adopted, it would be appropriate to use potent statins at high doses (ie, atorvastatin 80 mg or rosuvastatin 40 mg).
Study Limitations
Of the trials identified, the sole investigators who declined to participate in the patient-level analysis were Veselka et al, 22 ie, the authors of 1 of the 2 studies in which a significant clinical benefit by statin pretreatment was not demonstrated. Although their data were entered in the trial-level analysis and did not affect the overall results, lack of inclusion in the patient-level analysis may represent a study limitation. Another limitation is that the included studies used different dosing strategies of statins, and the time points at which cardiac markers were measured after PCI were variable. Moreover, 4 of the 13 studies 22, 24, 26, 28 did not collect 30-day data, and the MACE for those 4 studies only included periprocedural myocardial infarction. Finally, because the antithrombotic treatments used in the various trials appear to be different, the robustness of meta-driven conclusions may be limited and the clinical benefit of high-dose statins observed in the present meta-analysis may be affected; a standardized approach to antithrombotic therapies in a larger randomized trial would help eliminate this confounder.
Conclusions
Cost-effectiveness analysis of the initiation of statin therapy before PCI would likely be very favorable, because there was no risk excess associated with high-dose loading with statins before the procedure (none of the trials reported significant side effects), and the cost of a few doses of statin is negligible. The consistency across the trials and the strength of the effect observed in the present meta-analysis suggest that a strategy of high-dose statin pretreatment should be used routinely in patients undergoing PCI, irrespective of clinical presentation and chronic statin therapy; guideline committees should consider updates to incorporate this novel strategy for peri-PCI prevention of ischemic events.
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